Percutaneous hepatic arterial infusion (HAI) of mitomycin C and floxuridine (FUDR)

An effective treatment for metastatic colorectal carcinoma in the liver

Y. Z. Patt, G. M. Mavligit, V. P. Chuang, S. Wallace, S. Johnston, R. S. Benjamin, M. Valdivieso, Evan M Hersh

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

The response rate of metastatic colorectal carcinoma confined to the liver to HAI of FUDR alone is at the range of 50% and to mitocycin C by hepatic arterial infusion (HAI) at the range of 35%. Mitomycin C was added to FUDR by continuous infusion and given by HAI to 12 patients with colorectal cancer confined to the liver. Catheters were placed subselectively in the hepatic artery, and infusion continued for five to six days when the catheter was removed. Cycles were repeated every 30 days. Chemotherapy consisted of mitomycin C 15 mg/m 2 administered on day 1 followed by FUDR 100 mg/m 2 by continuous infusion daily for five days. Response to treatment was evaluated by serial determination of plasma CEA and by imaging techniques consisting of a computerized tomography, sonography, and radionuclide scanning of liver as well as by angiography. In 2 patients, complete remission was achieved; in 4 patients a 75% and in another 4 patients a 50% decrease in liver metastasis was observed, while 2 patients had stable disease. Thus, a response rate of 83% with a median duration of six to seven months was achieved. The median survival of these patients was 16 months. Eight of the 12 patients have failed previous, i.v. 5-FU containing regimens. Complications related to 45 treatment cycles were the following: catheter displacement in 11.1%, an intimal tear, usually in the hepatic artery in 4.4%, gastric ulcerations in 5.4% and septicemia in 2.7% of the cycles. In addition, aneurysmal dilation of the hepatic artery occurred in 4 patients (8.8% of the treatment cycles), all of whom continued treatment. Chemotherapy-related complications included primarily thrombocytopenia and stomatitis. Mitomycin C + FUDR by hepatic arterial infusion is an effective treatment for colorectal carcinoma metastatic to the liver. The high response rate justified the adjuvant treatment of Dukes C colon cancer patients with this treatment.

Original languageEnglish (US)
Pages (from-to)261-265
Number of pages5
JournalCancer
Volume46
Issue number2
StatePublished - 1980
Externally publishedYes

Fingerprint

Floxuridine
Mitomycin
Colorectal Neoplasms
Liver
Hepatic Artery
Therapeutics
Catheters
Emission-Computed Tomography
Tunica Intima
Drug Therapy
Stomatitis
Fluorouracil
Thrombocytopenia
Colonic Neoplasms
Dilatation
Ultrasonography
Sepsis
Stomach
Angiography
Neoplasm Metastasis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Percutaneous hepatic arterial infusion (HAI) of mitomycin C and floxuridine (FUDR) : An effective treatment for metastatic colorectal carcinoma in the liver. / Patt, Y. Z.; Mavligit, G. M.; Chuang, V. P.; Wallace, S.; Johnston, S.; Benjamin, R. S.; Valdivieso, M.; Hersh, Evan M.

In: Cancer, Vol. 46, No. 2, 1980, p. 261-265.

Research output: Contribution to journalArticle

Patt, YZ, Mavligit, GM, Chuang, VP, Wallace, S, Johnston, S, Benjamin, RS, Valdivieso, M & Hersh, EM 1980, 'Percutaneous hepatic arterial infusion (HAI) of mitomycin C and floxuridine (FUDR): An effective treatment for metastatic colorectal carcinoma in the liver', Cancer, vol. 46, no. 2, pp. 261-265.
Patt, Y. Z. ; Mavligit, G. M. ; Chuang, V. P. ; Wallace, S. ; Johnston, S. ; Benjamin, R. S. ; Valdivieso, M. ; Hersh, Evan M. / Percutaneous hepatic arterial infusion (HAI) of mitomycin C and floxuridine (FUDR) : An effective treatment for metastatic colorectal carcinoma in the liver. In: Cancer. 1980 ; Vol. 46, No. 2. pp. 261-265.
@article{d758e430fc8f4a3eb27c196841e36fe4,
title = "Percutaneous hepatic arterial infusion (HAI) of mitomycin C and floxuridine (FUDR): An effective treatment for metastatic colorectal carcinoma in the liver",
abstract = "The response rate of metastatic colorectal carcinoma confined to the liver to HAI of FUDR alone is at the range of 50{\%} and to mitocycin C by hepatic arterial infusion (HAI) at the range of 35{\%}. Mitomycin C was added to FUDR by continuous infusion and given by HAI to 12 patients with colorectal cancer confined to the liver. Catheters were placed subselectively in the hepatic artery, and infusion continued for five to six days when the catheter was removed. Cycles were repeated every 30 days. Chemotherapy consisted of mitomycin C 15 mg/m 2 administered on day 1 followed by FUDR 100 mg/m 2 by continuous infusion daily for five days. Response to treatment was evaluated by serial determination of plasma CEA and by imaging techniques consisting of a computerized tomography, sonography, and radionuclide scanning of liver as well as by angiography. In 2 patients, complete remission was achieved; in 4 patients a 75{\%} and in another 4 patients a 50{\%} decrease in liver metastasis was observed, while 2 patients had stable disease. Thus, a response rate of 83{\%} with a median duration of six to seven months was achieved. The median survival of these patients was 16 months. Eight of the 12 patients have failed previous, i.v. 5-FU containing regimens. Complications related to 45 treatment cycles were the following: catheter displacement in 11.1{\%}, an intimal tear, usually in the hepatic artery in 4.4{\%}, gastric ulcerations in 5.4{\%} and septicemia in 2.7{\%} of the cycles. In addition, aneurysmal dilation of the hepatic artery occurred in 4 patients (8.8{\%} of the treatment cycles), all of whom continued treatment. Chemotherapy-related complications included primarily thrombocytopenia and stomatitis. Mitomycin C + FUDR by hepatic arterial infusion is an effective treatment for colorectal carcinoma metastatic to the liver. The high response rate justified the adjuvant treatment of Dukes C colon cancer patients with this treatment.",
author = "Patt, {Y. Z.} and Mavligit, {G. M.} and Chuang, {V. P.} and S. Wallace and S. Johnston and Benjamin, {R. S.} and M. Valdivieso and Hersh, {Evan M}",
year = "1980",
language = "English (US)",
volume = "46",
pages = "261--265",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Percutaneous hepatic arterial infusion (HAI) of mitomycin C and floxuridine (FUDR)

T2 - An effective treatment for metastatic colorectal carcinoma in the liver

AU - Patt, Y. Z.

AU - Mavligit, G. M.

AU - Chuang, V. P.

AU - Wallace, S.

AU - Johnston, S.

AU - Benjamin, R. S.

AU - Valdivieso, M.

AU - Hersh, Evan M

PY - 1980

Y1 - 1980

N2 - The response rate of metastatic colorectal carcinoma confined to the liver to HAI of FUDR alone is at the range of 50% and to mitocycin C by hepatic arterial infusion (HAI) at the range of 35%. Mitomycin C was added to FUDR by continuous infusion and given by HAI to 12 patients with colorectal cancer confined to the liver. Catheters were placed subselectively in the hepatic artery, and infusion continued for five to six days when the catheter was removed. Cycles were repeated every 30 days. Chemotherapy consisted of mitomycin C 15 mg/m 2 administered on day 1 followed by FUDR 100 mg/m 2 by continuous infusion daily for five days. Response to treatment was evaluated by serial determination of plasma CEA and by imaging techniques consisting of a computerized tomography, sonography, and radionuclide scanning of liver as well as by angiography. In 2 patients, complete remission was achieved; in 4 patients a 75% and in another 4 patients a 50% decrease in liver metastasis was observed, while 2 patients had stable disease. Thus, a response rate of 83% with a median duration of six to seven months was achieved. The median survival of these patients was 16 months. Eight of the 12 patients have failed previous, i.v. 5-FU containing regimens. Complications related to 45 treatment cycles were the following: catheter displacement in 11.1%, an intimal tear, usually in the hepatic artery in 4.4%, gastric ulcerations in 5.4% and septicemia in 2.7% of the cycles. In addition, aneurysmal dilation of the hepatic artery occurred in 4 patients (8.8% of the treatment cycles), all of whom continued treatment. Chemotherapy-related complications included primarily thrombocytopenia and stomatitis. Mitomycin C + FUDR by hepatic arterial infusion is an effective treatment for colorectal carcinoma metastatic to the liver. The high response rate justified the adjuvant treatment of Dukes C colon cancer patients with this treatment.

AB - The response rate of metastatic colorectal carcinoma confined to the liver to HAI of FUDR alone is at the range of 50% and to mitocycin C by hepatic arterial infusion (HAI) at the range of 35%. Mitomycin C was added to FUDR by continuous infusion and given by HAI to 12 patients with colorectal cancer confined to the liver. Catheters were placed subselectively in the hepatic artery, and infusion continued for five to six days when the catheter was removed. Cycles were repeated every 30 days. Chemotherapy consisted of mitomycin C 15 mg/m 2 administered on day 1 followed by FUDR 100 mg/m 2 by continuous infusion daily for five days. Response to treatment was evaluated by serial determination of plasma CEA and by imaging techniques consisting of a computerized tomography, sonography, and radionuclide scanning of liver as well as by angiography. In 2 patients, complete remission was achieved; in 4 patients a 75% and in another 4 patients a 50% decrease in liver metastasis was observed, while 2 patients had stable disease. Thus, a response rate of 83% with a median duration of six to seven months was achieved. The median survival of these patients was 16 months. Eight of the 12 patients have failed previous, i.v. 5-FU containing regimens. Complications related to 45 treatment cycles were the following: catheter displacement in 11.1%, an intimal tear, usually in the hepatic artery in 4.4%, gastric ulcerations in 5.4% and septicemia in 2.7% of the cycles. In addition, aneurysmal dilation of the hepatic artery occurred in 4 patients (8.8% of the treatment cycles), all of whom continued treatment. Chemotherapy-related complications included primarily thrombocytopenia and stomatitis. Mitomycin C + FUDR by hepatic arterial infusion is an effective treatment for colorectal carcinoma metastatic to the liver. The high response rate justified the adjuvant treatment of Dukes C colon cancer patients with this treatment.

UR - http://www.scopus.com/inward/record.url?scp=0018895404&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018895404&partnerID=8YFLogxK

M3 - Article

VL - 46

SP - 261

EP - 265

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 2

ER -